Group items tagged

High potency active pharmaceutical ingredients are molecules widely used in the production of hormonal drugs which are used for the treatment of breast cancer. It is also used in the central nervous system drugs, cardiovascular drugs, and musculoskeletal drugs. Moreover, recently they have been also gaining demand in the gynecology & cosmetics industry. These drugs are segmented into innovative and generic. The growing prevalence of cancer is predominantly fueling the growth of the high potency active pharmaceutical ingredients market. The increasing number of the pharmaceutical industry coupled with the growing investment in the research and development activities conducted by the pharmaceutical industry is again contributing to the market growth. Moreover, increasing use of high potency active pharmaceutical ingredients as antibody-drug conjugates as it is one of the most important and effective treatments for cancer is also projected to augment the market growth. It is also used to treat glaucoma which is further anticipated to foster the growth of the high potency active pharmaceutical ingredients market. From the geographical point of view, North America is expected to gain significant growth over the forecast period and this is attributed to the high prevalence of chronic disease in the region. Read more @ https://sachinbhombe.blogspot.com/2021/03/high-potency-active-pharmaceutical.html

Biopharmaceuticals contract manufacturing refers to pharmaceutical companies outsourcing the development and manufacturing of drugs. It is driven by the use of advanced technologies, scientific advances, and d a highly complex research and development enterprise. It provide wide range of manufacturing services to biopharmaceutical companies. Biopharmaceutical contract manufacturing is widely used due to the complexity in manufacturing of biomolecules, as are considerably more complex, different in shape, size, and behavior than pharmaceuticals. Contract manufacturing organizations (CMOs) provide services from development of biologics to commercial scale production. Biopharmaceutical contract manufacturing involves the production of medicines in small units that can be customized to meet customer specifications. Contract manufacturers usually produce high quality and highly secure pharmaceuticals at low prices. The primary components of these drugs are plant materials and chemical substances. Biopharmaceutical companies are focused on producing numerous pharmaceuticals for the pharmaceutical industry. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2021/03/biopharmaceutical-contract.html

A pharmaceutical drug is a chemical substance that is used to cure, diagnose, treat, or protect disease. Some pharmaceutical drugs are sold in pharmacies and some are sold over-the-counter or as over-the-counter medications. Prescription drugs have many different applications, including the treatment of certain illnesses, but they also come in various forms that range from capsules, tablets, liquids, and lotions. One of the most popular and major types of pharmaceutical drugs is the oral form. These are drugs that can be taken by swallowing, which means that they need to pass through the stomach into the upper intestines where they are metabolized and digested into other substances. It is important to note that a certain amount of stomach acid is normal in the intestines and it helps digest food. Another popular type of pharmaceutical drug is an injectable. These are available as intravenous fluids and can be injected into a vein or through a catheter to deliver drugs to the body. Many people opt for these drugs because of their convenience and ability to be delivered right to where they need it. There are also synthetic drugs that can be used to treat many of the problems faced by the body. These drugs are sometimes more expensive than the ones prescribed from a doctor but are considered to be safer since they do not have as many side effects. Also, some of these drugs are more reliable than the prescription medication provided by a doctor. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/emergence-of-covid-19-adversely-impacts.html

"India Pharmaceuticals & Healthcare Report" provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Indian pharmaceutical and healthcare industry.

Seminar on Analytical Instrument Qualification and Validation: Understanding to Prepare for FDA Audits to become Part 11 Compliant at Boston, MA Course "Analytical Instrument Qualification and Validation: Understanding to Prepare for FDA Audits to become Part 11 Compliant" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: In this two day workshop conference you will learn the different global agencies expectations of analytical equipment qualification along with the development of a sound process validation program in order to develop and implement bulletproof solutions that are accepted, effective, and efficient. Through case study analysis we will examine best practices to provide thoughts and ideas to develop or improve the performance of your current system. Additionally, case studies will explore how your management practices of your analytical equipment qualification/ validation and process validation programs can help or hurt your legal liability and the legal issues that arise from nonconformance with regulators and Auditors. This seminar will help attendees understand the instrument qualification and system validation processes and will provide instruction on how to prepare for FDA audits and how to become part 11 compliant. Why should you attend? The cost of non-compliance is therefore more than that of compliance. Are you in compliance with the FDA regulations for analytical equipment qualification and validation in your facility? Areas Covered in the Session: * Learn about the regulatory background and requirements for laboratory instrument qualification and system validation * Understand the logic and principles of instrument qualification and system validation from validation planning reporting * Understand and be able to explain your company's qualification and validation strategies * Be able to independently prepare execute test protocols, this includes s

Overview: Many infectious diseases were historically confined to specific geographical regions. However, some now pose global threats due to ease of travel, globalization of trade and commerce and global warming. Government Agencies, non-Profit Organizations, Philanthropic groups and others are also funding vaccination programs for regions where infectious diseases are endemic and to deal with new outbreaks.. Such developments are stimulating research in and the development of improved vaccines, their manufacture and control. Supply Chain complexities and stability issues need to be addressed to cope with transport of vaccines to and their use in climatically hostile regions. Programs to address such challenges need to be implemented, being resourced by appropriately trained and qualified staff from a number of disciplines. Development programs for immuno oncology products also require staffing by similarly skilled professionals. Workers currently engaged in Discovery, Development and Manufacture of conventional medications , or those seeking career-change opportunities can develop an understanding of the concepts, constraints and opportunities associated with Vaccine products by attendance at the Webinar. Engineering professionals involved in facility construction, or repurposing can also benefit as can Regulatory Affairs Professionals or staff at medicines Evaluation Agencies. The subject matter is particularly suited to professionals who are expert in the various disciplines associated with conventional medications ("so-called "small molecules") who wish to expand and develop their skills by involvement in vaccine-related programs including immuno-oncology. Areas Covered in the Session: History of and development of vaccine concepts. undamentals of vaccination Vaccine Types Administration of Vaccines Future Concepts Immuno-Oncology Vaccine Manufacture Who Will Benefit: Regulatory Affair Managers Project Management Personnel QA Managers Scientists Technol

Course "Key Factors to Write an Effective Standard Operating Procedure (SOP) and Work Instructions (WIs)" has been pre-approved by RAPS as eligible for up to 12 credits towards a participant's RAC recertification upon full completion. Overview: Writing SOPs or procedural documents can be challenging at times. However, writing SOPs is overall a straightforward process. However, enforcing what you already created and implemented in the pipeline is another story. The term SOP is very obvious. We have seen "clearly written description of how specific tasks are to be done." Another satisfactory definition would be "detailed written instructions that achieve the uniformity of the performance of a specific function." Is the firm doing what the regulations specify? Is the firm doing what their procedures specify? If you are medical device or a pharmaceutical manufacturer, these definitions come as no surprise because when it comes to FDA regulations and guidance documents "establish" means to define, to document (in writing or electronically) and to implement. The goal and emphasis with FDA is simple. Proof of "Establish" is the foundation. Is the firm doing what the regulations specify? Is the firm doing what their procedures specify? Are the procedures being followed and enforced by company personnel? SOPs are needed in regulated industries to give step-by-step instructions for performing a particular job or task. This session will provide a step-by-step overview and a snapshot of the procedure description, the process and format. The subject matter of a SOP may range from how to operate a piece of machinery to how to log into a particular software program. SOPs ensure consistency and reliability because they require training of all affected parties. This session will address recent enforcement actions for SOP related violations but no surprise. Most of our enforcement actions are documentation related, i.e., SOP or other procedural documents. We will review examples from

GlaxoSmithKline Pharmaceuticals Ltd is investing Rs 1,000 crore in a new state-of-the-art pharmaceutical unit in Karnataka ...

The Common Technical Document (CTD) is an international standard for the summary documents relating to quality, safety and efficacy information of medicinal products. The CTD is mandatory for the registration of medicines. International Council for Harmonization (ICH) mandates to obtain regulatory approval of new drug applications of Pharmaceutical companies operating in European Union states. The main aim of CTD is to achieve greater harmonization in new drugs development and registration. The standard encompasses the entire spectrum of documentation to be integrated into a regulatory submission dossier, thereby offering complete guidance to pharmaceutical companies as to how formulation and manufacturing information supporting the quality parameter as well as the results of non-clinical and clinical research needs to be organized and presented.

Pharmacovigilance, also called clinical pharmacology, is the clinical use of a drug in treating patients with certain disorders and diseases. Adverse drug events (ADRs), which include deaths from drug toxicity, can lead to severe medical consequences, as revealed in numerous studies about adverse drug reactions (ADR). To increase awareness about and educate patients about ADRs, more research in the area of ADRs and pharmacovigilance is required. In June 2020, the Food and Drug Administration (FDA) published a notice of intent to implement the National Pharmacy Ownership and Clinical Quality Improvement Organizations (NPHIA) guidelines on the regulation of pharmaceuticals and other medical products. The intention was to standardize the labeling and marketing of prescription and non-prescription drugs. The move resulted in the formation of the National Pharmacy Ownership and Clinical Quality Improvement Organizations (NPZA) and the National Institute for Drug Evaluation (NIDA). Although the new regulations established guidelines for the safe handling of pharmaceuticals, the problems still exist. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2021/01/how-pharmacovigilance-reduce-rate-of.html

A companion animal is a non-assistive animal used for psychological support, amusement, company, extrovert display, and several other functions that a human needs to share with animals. Dogs, cats, horses, birds, mice, and guinea pigs are some of the animals that can be considered as companion animals. Numerous studies have shown that positive health benefits, such as lowered blood pressure, decreased anxiety, decreased cardiac arrhythmias, greater psychological stability, and improved well-being are associated with owning a companion animal. Furthermore, companion animal pharmaceuticals are used to sedate, treat, and improve their health and performance. It is essential to take care of these animals and provide essential health services to them.

In order to become a safe and effective medicine, a compound has to travel through a lengthy process of rigorous testing. Over the last few decades, the amount of time required to develop and test a novel drug has increased drastically. However, the introduction of social media and digital technology into drug development have the ability to significantly expedite this process. This webinar will explore the policies and principles of using social media through the evolution of developing a pharmaceutical drug from its initial stages to its introduction into the market. This includes analyzing the methods in which pharmaceutical companies utilize social media during the planning process, identifying the best candidate for the lead compound in a drug, conducting animal and human testing, recruiting candidates for clinical trials.

Overview: The connection between the Body, its physiology and particularly biochemistry, have been linked to the mind with particular emphasis upon emotions and stress. This can be easily substantiated in common everyday situations. Anyone who has observed a facial red flush triggered by some sort of embarrassment can attest to the foregoing connection. The emotions and stress play a key role in many if not all diseases and disorders: due to the vastness of the subject, we will focus on the application of the mind/body connection(MBC) to skin. This serves as an introduction to the field of psych dermatology which, although still in its infancy in the USA, is expanding as evidence with regard to the psychological component related to the etiology of skin diseases continues to grow. Concurrently, the field of Alternative techniques IN mind/body treatments continue to grow in leaps and bounds providing effective methods for integration with conventional cosmetic and dermaceutical treatment. This provides a dual complimentary pathway both for prevention and treatment of any/most skin disorders. Expanding on this model, we have already shown how the mind influences the body as per the above example. This general proposition can be extended to include specific skin disorders such as acne rosacea psoriasis eczema and atopic dermatitis to name a few. We will concentrate on Acne for the sake of this discussion. First, focusing on the B component of the BMC model, the primary lesion associated with acne is the formation microcomodones, which are small enough to proceed undetected until larger comodones appear later in the cycle. The latter cycle is initiated by peroxidation of squalene and unsaturated fatty acids present in human sebum. This leads to the foregoing lesions and pro- inflammatory mediators such as cytokines and interleukins followed by an increase of p.acnes on the epithelial cell wall together with increased film formation of the p.acnes is the same area This

Prevalence of cancer is on the rise throughout the world. Advanced therapeutics are being developed by pharmaceutical companies to address the growing burden of cancer. The time and costs associated with oncology drug development are also increasing; hence the key companies are collaborating with other pharmaceutical companies to reduce these costs.

Biosimilars, also known as biologic products, are currently the fastest growing category of medical products in the United States, with sales estimated at more than $40 billion dollars annually. When prescribed by doctors, these products may provide more effective treatment options for patients suffering from a chronic disease or condition. In late August, the FDA held a forum on biosimilars. The topic was "biosimilar medications - what are they, how do they work, and are they safe and effective." Representatives from the FDA, pharmaceutical companies, and biotechnology organizations attended the forum. The forum included individuals who are leading the charge to register biosimilar products for clinical trials. According to the FDA, the agency will begin accepting applications for biologic drugs in late fall of 2020. In Japan, various manufacturers are focused on developing pipelines that contain biosimilar candidates aimed at treating various therapeutic conditions for patients in Japan. For instance, in December 2020, Alvotech and Japanese pharmaceutical company Fuji Pharma agreed on an extension on their exclusive strategic partnership for the commercialization of four biosimilar medicines in Japan. Read more @ https://coherentmarketinsights-cmi.blogspot.com/2020/12/biosimilars-and-impact-of-covid-19.html

The modern healthcare industry is the amalgamation of technology and medical services. With this growing trend of health IT, data security and privacy have become the main concerns for physicians. Be it, medical billing, MIPS & MACRA, electronic healthcare records (EHRs), digital collection and storage have taken the paramount place. Read More: https://www.p3care.com/blog/switching-towards-cloud-services-isnt-easy-for-pharmaceutical-industry/ Call us for medical billing services: (844) 557-3227 Visit us: https://goo.gl/maps/XPsjJvfmHzptEs9TA Tags: Medical Services Medical billing services, MIPS 2022, MACRA, MIPS Reporting, Healthcare

The Department of Industrial Policy and Promotion (DIPP) has released a statistic affirming Foreign Direct Investment in the region of pharmaceuticals and drugs. The value of investments will be around US $ 8.81 billion that comes to about Rs 48,828.3 crore in Indian currency. It is predicted that, the biotechnology industry will surpass 11.6 billion dollars by the year 2017

Drug delivery means different methods, approaches, technologies, formulations, and systems for transporting a pharmaceutical compound in the body to achieve desired therapeutic effects. There are different types of drug delivery including intravenous injectable, inhalation, or absorption. The injectable drug delivery is considered the most effective route of administration for the effective delivery of drugs to the targeted sites. This enhances the patient's compliance with the drug. This method of drug delivery boosts the drug adsorption from various sites including intravenous, subcutaneous, and intramuscular. Moreover, it increases the bioavailability of the drug at the systematic circulation of the drug at the designated site of action. The challenges of administering an injectable drug to an area are unique and complex. It is common practice to inject a small amount of a drug into the skin of a subject in order to administer a larger dose. However, many complications could occur if too much of a drug is injected at once. Since most of these systems are designed to administer large amounts over a long period of time, multiple injections could cause serious health problems, such as infection and damage to vital organs. The future injectable drug delivery will require the development of new methods for delivering medications, and the creation of new products that provide a safer, more effective environment for the delivery process. Read More @ https://coherentmarketinsights-cmi.blogspot.com/2020/11/injectable-drug-delivery-is-getting.html

Europe Blow Fill Seal Technology market is anticipated to grow appreciably at rate in the forecasted period. This is attributed to the rising demand for personalized medicine, increasing focus towards consumer protection, and growing adoption of Blow Fill Seal Technology (BFS) technology in the pharmaceutical industry. Blow Fill Seal (BFS) technology is a manufacturing process used in the pharmaceutical and healthcare industries to produce small, sterile, and sealed containers for liquid or semi-solid products. It is a highly automated and efficient process that integrates container formation, filling, and sealing into a single continuous operation. Blow Fill Seal (BFS) technology is commonly used for the production of unit-dose containers for ophthalmic solutions, respiratory drugs, sterile injectables, nasal sprays, and other liquid or semi-solid pharmaceutical products.